Formulation design considerations for oral vaccines

Jitinder Wilkhu, Sarah E McNeil, Daniel J Kirby, Yvonne Perrie

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Whilst oral vaccination is a potentially preferred route in terms of patient adherence and mass vaccination, the ability to formulate effective oral vaccines remains a challenge. The primary barrier to oral vaccination is effective delivery of the vaccine through the GI tract owing to the many obstacles it presents, including low pH, enzyme degradation and bile-salt solubilization, which can result in breakdown/deactivation of a vaccine. For effective immune responses after oral administration, particulates need to be taken up bythe M cells however, these are few in number. To enhance M-cell uptake, particle characteristics can be optimized with particle size, surface charge, targeting groups and bioadhesive properties all being considerations. Yet improved uptake may not translate into enhanced immune responses and formulating particulates with inherent adjuvant properties can offer advantages. Within this article, we establish the options available for consideration when building effective oral particulate vaccines.

LanguageEnglish
Pages1141-1164
Number of pages24
JournalTherapeutic Delivery
Volume2
Issue number9
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Vaccines
Vaccination
Mass Vaccination
Aptitude
Patient Compliance
Bile Acids and Salts
Particle Size
Oral Administration
Gastrointestinal Tract
Enzymes

Keywords

  • oral vaccination
  • mass vaccination
  • M cells
  • adjuvant properties

Cite this

Wilkhu, Jitinder ; McNeil, Sarah E ; Kirby, Daniel J ; Perrie, Yvonne. / Formulation design considerations for oral vaccines. In: Therapeutic Delivery. 2011 ; Vol. 2, No. 9. pp. 1141-1164.
@article{a304eb7fee8043f18157c0d26b6128f9,
title = "Formulation design considerations for oral vaccines",
abstract = "Whilst oral vaccination is a potentially preferred route in terms of patient adherence and mass vaccination, the ability to formulate effective oral vaccines remains a challenge. The primary barrier to oral vaccination is effective delivery of the vaccine through the GI tract owing to the many obstacles it presents, including low pH, enzyme degradation and bile-salt solubilization, which can result in breakdown/deactivation of a vaccine. For effective immune responses after oral administration, particulates need to be taken up bythe M cells however, these are few in number. To enhance M-cell uptake, particle characteristics can be optimized with particle size, surface charge, targeting groups and bioadhesive properties all being considerations. Yet improved uptake may not translate into enhanced immune responses and formulating particulates with inherent adjuvant properties can offer advantages. Within this article, we establish the options available for consideration when building effective oral particulate vaccines.",
keywords = "oral vaccination, mass vaccination, M cells, adjuvant properties",
author = "Jitinder Wilkhu and McNeil, {Sarah E} and Kirby, {Daniel J} and Yvonne Perrie",
year = "2011",
month = "9",
doi = "10.4155/tde.11.82",
language = "English",
volume = "2",
pages = "1141--1164",
journal = "Therapeutic Delivery",
issn = "2041-5990",
number = "9",

}

Formulation design considerations for oral vaccines. / Wilkhu, Jitinder; McNeil, Sarah E; Kirby, Daniel J; Perrie, Yvonne.

In: Therapeutic Delivery, Vol. 2, No. 9, 09.2011, p. 1141-1164.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Formulation design considerations for oral vaccines

AU - Wilkhu, Jitinder

AU - McNeil, Sarah E

AU - Kirby, Daniel J

AU - Perrie, Yvonne

PY - 2011/9

Y1 - 2011/9

N2 - Whilst oral vaccination is a potentially preferred route in terms of patient adherence and mass vaccination, the ability to formulate effective oral vaccines remains a challenge. The primary barrier to oral vaccination is effective delivery of the vaccine through the GI tract owing to the many obstacles it presents, including low pH, enzyme degradation and bile-salt solubilization, which can result in breakdown/deactivation of a vaccine. For effective immune responses after oral administration, particulates need to be taken up bythe M cells however, these are few in number. To enhance M-cell uptake, particle characteristics can be optimized with particle size, surface charge, targeting groups and bioadhesive properties all being considerations. Yet improved uptake may not translate into enhanced immune responses and formulating particulates with inherent adjuvant properties can offer advantages. Within this article, we establish the options available for consideration when building effective oral particulate vaccines.

AB - Whilst oral vaccination is a potentially preferred route in terms of patient adherence and mass vaccination, the ability to formulate effective oral vaccines remains a challenge. The primary barrier to oral vaccination is effective delivery of the vaccine through the GI tract owing to the many obstacles it presents, including low pH, enzyme degradation and bile-salt solubilization, which can result in breakdown/deactivation of a vaccine. For effective immune responses after oral administration, particulates need to be taken up bythe M cells however, these are few in number. To enhance M-cell uptake, particle characteristics can be optimized with particle size, surface charge, targeting groups and bioadhesive properties all being considerations. Yet improved uptake may not translate into enhanced immune responses and formulating particulates with inherent adjuvant properties can offer advantages. Within this article, we establish the options available for consideration when building effective oral particulate vaccines.

KW - oral vaccination

KW - mass vaccination

KW - M cells

KW - adjuvant properties

U2 - 10.4155/tde.11.82

DO - 10.4155/tde.11.82

M3 - Article

VL - 2

SP - 1141

EP - 1164

JO - Therapeutic Delivery

T2 - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 9

ER -